4/6/2010

Massachusetts-based Selecta Biosciences, which builds nanotechnology structures for vaccines, has raised $15 million in new venture capital. The nanoparticles Selecta creates can trigger an immune response, which has the potential to "leapfrog biological vaccines," said Selecta's Executive Chairman Robert L. Bratzler.

Related Summaries